OUR VIEW · OPINION中文

Madrigal: our view and what our model says about 2030

By · AI-assisted, human-reviewed and edited · · Updated · 7 sources · Fact-checked · 9 min read (39 min with all details)

Our view

Madrigal has the first and best-selling MASH drug and has just reported its first profitable quarter, but it is still a one-drug company whose approvals rest on outcomes trials still to report. On our inputs, about five runs in six beat the hurdle. The result rests most on when generics arrive, on the 2028 confirmatory trial and on the market still paying a growth-biotech multiple in 2030; a cash-flow-only check is far lower.

Price, Nov 3 close
$396.32
Hurdle, end-2030
$567
Median value, end-2030
$860
P10–P90 range, end-2030
$487–$1,525
Simulations beating hurdle
84%
End below today's price
7%

Prices: official close, Nasdaq, Nov 3, 2026 · Company data: 10-Q, Sep 30, 2026 · What these numbers mean

Market data as of the Nov 3, 2026 close ($396.32). The hurdle and the probabilities depend on that price. Values per share at Dec 31, 2030, undiscounted, from 50,000 simulations.

Snapshot at the Nov 3, 2026 close

Market value
$9.2BIncluding convertible preferred and pre-funded warrants: $11.6B
Enterprise value
$8.6B
Price/sales
6.4×
P/E
n/m
Revenue growth
+93%
Net cash
$620M

Our calculation from the company's filings (latest: 10-Q for the quarter to Sep 30, 2026, filed Nov 3, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Sep 30, 2026. Price $396.32 (official close, Nasdaq); 23.2 million shares (common shares on the cover page of the 10-Q filed Nov 3, 2026). n/m = not meaningful (e.g. negative earnings).

Earlier versions

VersionPrice usedHorizonMedian valueP10–P90Beat chance
Nov 3, 2026THIS VERSION $396.32 (Nov 3, 2026) end-2030$860$487–$1,52584%

No earlier versions yet. Each row is frozen as published: when we update this view, the previous numbers stay here.

Version 1.22 · Nov 4, 2026

Editors hold this stock, and also Arrowhead, Viking and Alnylam, which this article mentions. Updated for the Q3 2026 results. Market data as of the Nov 3, 2026 close ($396.32); market value $9.2B on 23.2M common shares (Q3 10-Q cover). Including the convertible preferred and pre-funded warrants, which convert one-for-one: $11.6B. Latest filings: the 10-K for 2025, the Q3 2026 10-Q, the 2026 proxy and Forms 4 to mid-September 2026 and a Form 144 from late September.

Labels: Fact (filings or market data), Company (management claims), Analyst (named or consensus views), Our view (our reasoning). Each section ends with a confidence level.

Simulation result (value per share at Dec 31, 2030, undiscounted; 50,000 simulations):

  • P10 $487 · P50 $860 · P90 $1,525 (middle half $660–$1,145; mean $935).
  • Hurdle $567 (the end-2030 price that earns 9% a year from today): 84% of simulations beat it (about +21% a year at the median); 7% end below today’s price.
End-2030 value per share (undiscounted) P10 P25 P50 P75 P90 Mean P(beat 9%/yr) P(loss)
Without add-ons (launch parts, pipeline options) $445 $600 $765 $980 $1,260 $810 79% 8%
  • That is about 52% above the hurdle (the FY2030 price that would earn a 9% yearly return from today’s price) of $567: 84% of outcomes beat it and 7% lose money, with a median return of about 21% a year.
  • Caveat 1: about a tenth of the median comes from possible takeovers. Our model includes them at historical base rates, and they happen in a quarter of runs; the standalone median is ~$805.
  • Caveat 2: the 2030 exit multiple leans on Madrigal’s own history. As patent protection runs out, our model keeps at least half of Madrigal’s own multiple, and it counts protection once: the fade toward peers applies only to the premium that protection does not explain.
The same result in words, today's price and the defining event
  • Our simulation gives a middle outcome (P50) of $860 a share at end-2030. The middle half of outcomes (P25–P75) runs from $660 to $1,145, and the mean is $935.
  • Pending transformative event: No merger or spin-off is pending. The defining event is the MAESTRO-NASH OUTCOMES readout in compensated cirrhosis (F4c), now expected in late 2027 (earlier the company said only “2027”). Company: a positive result has the “potential to double” the Rezdiffra opportunity (investor presentation; paraphrased by the CFO) and would also support full approval in F2–F3. Nearer events: topline Phase 3 data in Q4 2026 for Inventiva’s lanifibranor, the first oral rival, and new Medicare Part D contracts from Q1 2027.
  • Price implies vs our model: Our simulation (50,000 runs): end-2030 value P25/P50/P75 of $660 / $860 / $1,145 a share, mean $935, against a $567 hurdle. Chance of beating a 9% yearly return 84%; chance of a loss 7%. Today’s $396 sits near the 7th percentile of outcomes. Exit multiple: Madrigal’s own forward-sales multiple, adjusted for growth, faded toward peers and cut for the patent life left (median 5.1× next year’s sales).

What would move the result (our simulation; where the median value per share would land for each outcome):

  • Year generics arrive (central 2034, range ~2032–2038): with early generics the median would move to about $751; with late generics, to about $995.
  • 2028 confirmatory outcomes trial (~93% chance of success): if it fails, the median would move to about $135.
  • Market valuation level at the 2030 exit (central: neutral): at the low end the median would move to about $745; at the high end, to about $984.
  • F4c cirrhosis label (52% chance): with the label the median would move to about $955; without it, to about $782.
  • Share of diagnosed patients on therapy at once (central 25%, range 15–35%): at the low end the median would move to about $775; at the high end, to about $922.

Our view in brief

  1. Madrigal sells Rezdiffra, the first and leading MASH drug: $1.43B of trailing sales (+50% in Q3), more than 55,850 US patients, and a first quarterly profit in Q3 2026 ($55.4M). The stock still fell 8% on the day of those results.
  2. Growth to 2028 comes from adding F2–F3 patients at a lower net price (discounts rose from ~20% to ~34% in H1 2026 and were ~32.5% in Q3; management expects the low end of the mid-to-high 30s for 2026 and about the high end in 2027). After that it hinges on the cirrhosis (F4c) trial, now due in late 2027, and on holding up against rivals arriving from 2028.
  3. The accounts were clean at the end-2025 audit, but cost of sales, receivables and recurring “one-time” licensing charges need watching. Market value is $9.2B on common shares and $11.6B including the convertible preferred and pre-funded warrants, which convert one-for-one.
  4. At $396 (EV about $11.0B on all economic shares, 6.9× expected 2026 sales), our simulation gives an end-2030 middle outcome of $860 a share (P25–P75 $660–$1,145; mean $935) against a $567 hurdle: an 84% chance of beating a 9% yearly return and a 7% chance of a loss. The result leans on the 2030 exit multiple; a cash-flow-only check gives a median of ~$340.
  5. Watch lanifibranor’s Phase 3 data in Q4 2026, rebates in 2027 as new Medicare contracts start, the patent-extension decision and any generic challenges from March 2028 (generic timing is the biggest driver), the F4c readout in late 2027 and the 2028 confirmatory trial.
  6. Survival is not the question: Madrigal could get through a bad year without raising money, and its real call on cash is future licensing deals. The full facts are in Madrigal’s Long View → /stocks/mdgl/long-view/

1. The business in one paragraph

Madrigal sells one drug, Rezdiffra, a once-daily pill for MASH in patients with moderate to advanced liver scarring (F2–F3), and almost all sales are in the US. That is why our model is built around Rezdiffra’s US patient count, its net price and the trials that must confirm its accelerated approvals. The full facts are in Madrigal’s Long View → /stocks/mdgl/long-view/

The facts behind this

Madrigal sells one drug, Rezdiffra (resmetirom), a once-daily pill for MASH, a fatty-liver disease that scars the liver. Rezdiffra is approved for adults with moderate to advanced scarring (stages F2–F3) but not cirrhosis. Net sales were $958M in 2025 and $431M in Q3 2026 (+50% year on year), and the trailing 12 months reached $1.43B (our calculation). Almost all sales are in the US.

  • Approvals (Fact): the FDA granted accelerated approval in March 2024 and the EU granted conditional approval in August 2025. Both approvals rest on 52-week biopsy results, so they still have to be confirmed by outcomes data.
  • Patients and channel: more than 55,850 US patients were on the drug at the end of September. Sales go through a handful of specialty pharmacies.
  • Europe: Germany launched in September 2025, and the UK regulator approved Rezdiffra in June 2026. Europe is “negligible” for 2026 (Company, Q2 call).
  • Royalty: Madrigal pays Roche, which discovered the molecule, a tiered single-digit royalty on sales.
  • Pipeline: since mid-2025 it has spent about $255M on upfront payments to license a pipeline built around combinations with Rezdiffra: an oral GLP-1 (MGL-2086, from CSPC), a DGAT-2 inhibitor (ervogastat, from Pfizer), MGL-0795 (a PNPLA3-targeting siRNA from Arrowhead) and six early siRNA programmes (from Ribocure).

Confidence: high.

2. Where growth comes from (3–5 years)

Growth to 2028 is a patient-adds and net-price question that consensus covers well, so our model stays close to it. After 2028 it depends on how fast the diagnosed pool fills and on rivals, which is where our inputs carry most of the uncertainty; F4c adds little before 2030.

The facts behind this

Growth through 2028 comes from adding patients in the current F2–F3 label at a lower net price. Growth after that depends on the F4c trial and on holding share as rival drugs launch from 2028.

Drivers, from most to least certain:

  • More F2–F3 patients (Fact/Company). Net patients on therapy went from 36,250 at end-2025 to 55,850 at the end of September, adding about 6,000–7,000 a quarter. Company: about 315,000 diagnosed F2–F3 patients were under the care of its target specialists before launch, about 460,000 at the end of 2025 and more than 530,000 by mid-2026, and it expects more than 30% growth this year. Our model starts from about 545,000, that estimate rolled forward to the end of September at our 12% yearly growth (range 8–20%). It estimates about 10% of diagnosed patients are treated. Management cites 60–70% one-year persistence, typical for a well-tolerated oral drug. The field force added endocrinologists in Q4 2025.
  • Lower net price per patient (Fact/Company). Gross-to-net discounts rose from about 20% in 2025 (our calculation from the reserve note) to about 34% in H1 2026 (~35% in Q1, ~32% in Q2) and ~32.5% in Q3 on the same method. Management now expects the low end of the “mid-to-high 30s” for 2026 and “plus or minus the high end” in 2027, as new Medicare Part D contracts start in Q1 2027 (CFO, Q3 call). Annualised net revenue per patient was about $32,900 in Q3 (Our calculation on average patients; list price about $50,873 a year as of April, up from $47,400 at launch).
  • F4c label (Company). The OUTCOMES trial has an estimated 845 patients (ClinicalTrials.gov; randomised 3:1) and an event-driven composite outcome endpoint. Madrigal now expects the data in late 2027 and plans a second cirrhosis outcomes trial, MAESTRO-CSPH, from the first half of 2027. A label could follow in late 2028 or 2029.
  • Europe and the pipeline. Europe will be slow because of pricing negotiations, and management links the delay to US most-favoured-nation pricing policy. The pipeline adds nothing before 2030 (section 4).

Size of the opportunity. These patient counts are the company’s own estimates of its market, from claims data (10-Q and the Q3 call); we use them as given and have not checked them independently. For cirrhosis (F4c), the company now estimates about 360,000 patients, up from the 245,000 it gave earlier; our model starts from about 370,000, rolled forward the same way. An independent published model (Estes et al., Hepatology, 2018) projected US MASH prevalence rising from about 16.5M people in 2015 to 27M by 2030, with advanced-fibrosis and cirrhosis cases growing fastest. Our view: the disease pool is not the constraint. The constraints are diagnosis rates and payers.

Consensus path (Analyst, MarketScreener/S&P Global, 19 analysts, before the Q3 results):

2025A 2026E 2027E 2028E 2030 (fallback)
Net sales ($B) 0.96 1.53 2.12 2.86 ~4.8 (one unnamed aggregator series; low confidence)
Growth 432% 59% 39% 35%
EBIT ($M) −300 −186 159 663
EPS ($) −12.85* −6.26 5.20 20.89
Free cash flow ($M) −190 −201 272 801

*As originally reported on common shares only. On the restated basis (including preferred and pre-funded warrants) it is −$10.15. The 2026E consensus is on the restated ~29.1M basis, so the two columns are not comparable.

Fallback where long-range consensus isn’t public: named views range from Evercore ISI’s $2.6B for 2030 (made in 2024, now stale) to Citizens’ Jonathan Wolleben at “above $6B” peak, excluding F4c. Our simulation’s median for 2030 is ~$4.1B (section 7): F2–F3 net adds start at today’s ~6,500 a quarter and bend to ~4,200 by 2030 as the diagnosed pool fills and rivals launch, with little from F4c before 2030.

Track record (Fact). The commercial record is strong, but the company gives no numeric guidance.

  • Sales beat consensus in Q4 2025 ($321M vs about $311M), Q1 2026, Q2 2026 ($364M vs about $350M) and Q3 2026 ($431.3M vs about $404M, FactSet). Madrigal still gives no numeric guidance; its CFO said she feels good about the consensus growth rate into Q4.
  • Product timelines have been met. Approval came on the PDUFA date. MGL-2086 entered the clinic in Q2 2026 as promised. The first Ribocure candidate was nominated in July 2026. F4c was guided to 2027 once enrollment finished; it is now expected in late 2027.
  • The weak spots were the February 2026 gross-to-net step-up (the stock fell 11% on the day) and a sequential sales dip in Q1 2026 ($321M → $311M).

Patient-base quality (replaces “backlog” for a drug company). There is no contracted backlog. Revenue is the patient base times net price, and the patient count is reported net of discontinuations, with no breakdown of starts or stops. Our view: in the simulation F4c is only ~2% of median 2030 sales (its value comes mostly after 2030), and all sales depend on a confirmatory trial (MAESTRO-NASH, 54 months, 2028). The bigger swings are how fast the diagnosed pool fills and when generics arrive.

Confidence: medium. The near term is well covered by consensus; 2029–30 is thin.

3. The edge (moat)

Rezdiffra’s edge is real but time-limited, and our model limits it in two ways: rivals take a share of new starts from 2028, and generic entry (central 2034) cuts the exit multiple. The company’s “protection into 2045” claim does not change our generic dates, because the late patents cover methods of use.

The facts behind this

Rezdiffra’s edge is real but time-limited: it is the only liver-directed oral pill, it was first, and it is the only drug with a fully enrolled cirrhosis outcomes trial. Injectable GLP-1s are a partial substitute. From 2028, other oral and injectable drugs arrive.

Why doctors use it (Company/Analyst): it is a once-daily pill, works whether or not patients lose weight, has good tolerability, and acts directly on the liver. Leerink reported that about 25% of Rezdiffra patients also take a GLP-1 and half have tried one. Its read is that Rezdiffra is being added to GLP-1s, not replaced by them. Company: under 1% of weekly Wegovy prescriptions are written by hepatologists or GIs for MASH.

Competition by drug (Fact unless noted; the 10-K confirms Phase 3 programmes at Novo, Inventiva, Roche, Lilly and Boehringer):

Drug (company) Type Status Our read
Wegovy (Novo Nordisk) Weekly GLP-1 injection FDA approved for F2–F3 MASH in August 2025 Biggest near-term substitute for metabolic patients; so far co-used more than displacing
Lanifibranor (Inventiva) Oral pan-PPAR NATiV3 topline Q4 2026; filing H1 2027; US launch possibly 2028 (Company, Inventiva) First oral rival; management cites weight gain and edema (Company claim)
Efruxifermin (Novo, via Akero, $4.7B upfront plus a CVR, up to ~$5.2B, 2025) FGF21 injection Phase 3 SYNCHRONY incl. F4 outcomes; Novo targets launch “before end of decade” Strongest threat in cirrhosis if its F4 data hold
Pegozafermin (Roche, via 89bio) FGF21 injection Phase 3 Same class as efruxifermin
Survodutide (Boehringer/Zealand) GLP-1/glucagon injection Phase 3 LIVERAGE and LIVERAGE-Cirrhosis; no MASH topline yet Up to 63.1% liver-fat reduction vs 24.5% on placebo in a ~25-per-arm MRI sub-study of an obesity trial (Jun 2026)
VK2809 (Viking; editors hold VKTX) Oral THR-β, same class as Rezdiffra Positive Phase 2b (2024); no MASH Phase 3 started (medium confidence) Same mechanism; relevant as a potential partner’s asset

Patents and loss of exclusivity (Fact, 10-K/10-Q; Our view on dates):

Protection Expiry Notes
NCE exclusivity Mar 14, 2029 Generic Paragraph IV filings allowed from Mar 14, 2028. A 30-month stay could run to about Sep 2031
Composition-of-matter (US 7,452,882, Roche) Sep 12, 2026 before extension FDA set a regulatory review period of 4,913 days (Federal Register, January 2026). A patent-term-extension decision is pending; the notice covers both ’882 and ’861, but only one can be extended. The applicant “seeks 1,594 days or 5 years” (Federal Register). Our view: up to 5 years, so roughly 2031 (’882) or to about Mar 2038 (’861, capped at 14 years after approval)
Solid form, use and manufacturing patents Sep 2033 Four Orange Book patents
Dosing and label patents 2042–2045 Weight-based dosing (to Feb 2045), statin dosing (2042), CYP2C8 step-down (2045), F4c method of use (2042, not yet Orange-Book relevant)

Our view: the company calls this “protection into 2045”, but those late patents are method-of-use claims, which generics can challenge or avoid with a “skinny label” that leaves out the patented use. Management says the safety language in the label makes skinny labels harder (Company). Realistic protection runs to the early-to-mid 2030s, with litigation starting in 2028. The Roche amendment (Jan 2026) gave Madrigal control of extension filings. In exchange, the Roche royalty is not reduced until those extensions expire.

Pricing and reimbursement: the 2026 first-line payer contracts bought access in exchange for rebates. The IRA’s Medicare negotiation rules would make Rezdiffra eligible for selection about seven years after approval. Our calculation: selection in early 2032 at the earliest, with a negotiated price from 2034, unless the “pill penalty” fix proposed in the April 2025 executive order becomes law. Madrigal doesn’t disclose the Medicare share of revenue. Asked about Rezdiffra volume on the Q3 2025 call, the CEO said the company anticipated about 30–35% Medicare.

Confidence: medium.

4. The worst realistic risk

The worst realistic case is a failed F4c trial in 2027 followed by rivals and rising rebates; the tail risk is a failed confirmatory trial in 2028 that puts the approval itself in question. Our model treats the first as roughly a coin flip and the second as a rare event that is the largest single downside.

The facts behind this

The worst realistic case is a failed or ambiguous F4c trial in 2027, followed by oral and injectable rivals in 2028–29 and rising rebates. That would leave a slowing, single-label drug facing generic litigation from 2028. A tail risk sits beyond that: the 2028 confirmatory trial fails and the accelerated approval comes into question.

Risk How likely (3–5 yrs) How bad Notes
F4c OUTCOMES fails or is ambiguous Medium High Benchmarks below. To our knowledge, no drug has yet shown a hard-outcome benefit in compensated MASH cirrhosis in Phase 3
Competition compresses share and price Medium–high Medium–high Lanifibranor data Q4 2026; FGF21s and incretins later; payer leverage grows with every entrant
Gross-to-net keeps rising (MFN, Medicaid GENEROUS model, IRA) Medium Medium Discounts went from ~20% to ~34% in one year
Confirmatory MAESTRO-NASH (54-month) fails in 2028 Low–medium Severe Accelerated approvals can be withdrawn: Intercept withdrew Ocaliva (PBC, accelerated approval) from the US in September 2025 at the FDA’s request, after confirmatory/outcomes data and safety signals
Capital allocation: serial licensing Medium Medium $255M of upfronts in 12 months; milestones of up to ~$7.4B (CSPC $2.0B, Ribocure $4.4B, Arrowhead $975M, Pfizer $70M+)

Probability-of-success benchmarks (attributed):

  • BIO/Informa/QLS (2021, all diseases, 2011–2020) put Phase 3→filing at 57.8% and filing→approval at 90.6%, about 52% from Phase 3 to approval. Phase 2→3 is 28.9% and Phase 1→approval 7.9%.
  • UBS analysts (in October) raised its F4c probability of success to 60% from 20% when it lifted its target to $735.
  • Our view: MASH cirrhosis trials have a poor history (selonsertib, simtuzumab, belapectin and obeticholic acid all missed), but Rezdiffra’s open-label data (2–3% yearly event rate vs a 5–10% placebo assumption, Company) are encouraging. We treat F4c as a coin flip, roughly 45–60%.

Pipeline and catalysts (Fact/Company):

Programme Mechanism Phase Next readout / step vs. plan
Rezdiffra F4c (MAESTRO-NASH OUTCOMES) THR-β 3 (845 pts, event-driven) Topline late 2027 On plan
Rezdiffra F2–F3 confirmatory (MAESTRO-NASH) THR-β 3 (54-month outcomes) 2028 On plan
MGL-2086 (from CSPC) Oral GLP-1 1 (SAD, dosed Jun 2026) Phase 1 data 2027; Phase 2 combination 2027 On plan
Ervogastat (from Pfizer) Oral DGAT-2 DDI study 4Q26 Phase 2 combination 2027 On plan
MGL-0795 (from Arrowhead; editors hold ARWR) PNPLA3 siRNA Phase 1 done FDA consultation; Phase 2 combination 2027 New (May 2026)
Ribocure siRNAs (six) siRNA Preclinical First candidate nominated Jul 2026 On plan

Legal/regulatory docket (Fact):

Issue Status Accrued Next date
Litigation A former employee sued in October 2026, alleging whistleblower retaliation after raising internal concerns about “certain Company data and reporting practices.” Madrigal disputes it and says it doesn’t currently expect pending proceedings to have a material adverse effect. It adds that there can be no assurance future developments won’t have a material impact (Q3 10-Q, note 11). An allegation, with no finding reported in this filing. Not disclosed —
Patent term extension (’882/’861) FDA review period published; due-diligence petition window closed in July 2026 n/a USPTO decision, date unknown
Generic challenges Not yet possible n/a Paragraph IV window opens Mar 14, 2028
Accelerated approval confirmation Post-marketing commitment n/a 2027 (via F4c) or 2028
EU conditional approval Annual renewal; outcomes data to EMA n/a 2027–28
Drug pricing (MFN, GENEROUS, IRA) Policy risk n/a Ongoing; IRA earliest ~2032 (our calculation)
Dependence map (Fact): five specialty pharmacies and distributors make up 89% of gross sales; one supplier makes the active ingredient; one lender
  • Customers: five specialty pharmacies and distributors made up 89% of H1 2026 gross sales (29%, 19%, 15%, 13%, 13%). A fifth customer rose from ~2–3% to ~12–13% in a year and is not named. Customer letters are not stable between filings: the Q1 10-Q shows the fast-growing customer as “D” (3% → 13%) and gives “E” as 15% a year earlier.
  • Suppliers: Evonik makes the active ingredient, with $239M of purchase commitments through 2029. UPM (primary US tablets) and Corden (EU, secondary US) make the tablets.
  • Licensor: Roche, which takes the royalty.
  • Payers: 2026 first-line access contracts with major commercial plans. Government: the Medicare and Medicaid share of revenue is undisclosed. Asked about Rezdiffra volume on the Q3 2025 call, the CEO said the company anticipated 50–55% commercial, 30–35% Medicare and about 10% Medicaid and other; we found no later figure.
  • Lender: Blue Owl, whose loan treats a change of control as an event of default.
  • China: the licensors CSPC and Suzhou Ribo carry geopolitical risk.

Survival check: Madrigal passes easily. The full facts on cash, debt and the funding path are in Madrigal’s Long View → /stocks/mdgl/long-view/

The facts behind this

Survival check (Fact/Our view): Madrigal passes easily. It could get through a bad year without raising money; the real call on cash is future licensing deals, not operations.

  • Cash and securities were $961M at the end of September against $350M of debt (Blue Owl term loan at SOFR+4.75%, 8.48% at the end of September, due July 2030, minimum cash covenant $100M).
  • It also has a $150M undrawn delayed-draw tranche to end-2027 and an unused $300M share-sale programme.
  • Free cash flow was −$190M in 2025 and −$152M in H1 2026, including about $85M of licensing upfronts. Free cash flow turned positive in Q2 (+$19.1M) and rose to +$116.6M in Q3 (our calculation), when operating income was positive for the first time ($56.0M). The CFO says profitability may “dip in and out” for now.

Confidence: medium–high on the facts, medium on probabilities.

5. Financial quality (read the notes)

The accounts were clean at the end-2025 audit, but several items make the near term look better than it will be: cost of sales is rising, receivables jumped in Q1, and “one-time” licensing charges recur, so our model treats licensing as an ongoing cost. Market value counts common shares; our per-share values use all economic shares, including the convertible preferred and pre-funded warrants, which convert one-for-one. The full facts are in Madrigal’s Long View → /stocks/mdgl/long-view/

The facts behind this

Q3 2026 in brief (10-Q): cost of sales 8.8% of net sales; operating income $56.0M, the first quarterly profit; free cash flow +$116.6M (our calculation); gross-to-net reserves $208.3M at the end of September. The table below covers the first half; the full Q3 facts are in Madrigal’s Long View.

Latest quarter in the table: Q2 2026 (10-Q), first half 2026 (same 10-Q) and full year 2025 (10-K). Pay and share-plan figures are from the 2026 proxy. Gross-to-net, days outstanding, percentages of sales and the Q2 free-cash-flow estimate are our calculations from those filings.

The accounts were clean in the usual sense at the end-2025 audit: controls were effective, PwC is the auditor, and there was no goodwill and no capitalised development (10-K). A former employee’s complaint from October 2026 raises concerns about data and reporting practices; it is an allegation, with no finding reported in the 10-Q (see the legal table in section 4). The key judgement is the gross-to-net estimate. PwC’s critical audit matter is product revenue recognition (driven by audit effort; it includes testing rebate and other variable-consideration items). Several items flatter the near-term picture: “one-time” licensing charges that recur, inventory expensed before approval, and cash timing from rebate accruals.

(10-K FY2025; 10-Q Q2 2026) 2025 H1 2026 Q2 2026
Net sales ($M) 958 676 364
Gross-to-net (our calc.) ~20% ~34% ~32% (our calc.; Q1 ~35%). FY2026 guide “mid-to-high 30s” (Company)
Cost of sales % of sales 5.9% 9.9% 11.0%
Operating loss ($M) −300 −149 −56
Stock-based pay ($M; % of sales) 98 (10%) 69 (10%) 35 (10%)
Free cash flow ($M) −190 −152 ~+20 (est.)

What the notes show:

  1. Revenue vs gross profit (10-Q). Gross margin is about 90%, but cost of sales is rising faster than sales: it went from 4% to 11% of sales in a year. The causes are the Roche royalty, a $10.4M Q2 write-down of work-in-process “that may not meet quality specifications”, and the run-off of inventory that was expensed as R&D before approval.
    • Excluding the $10.4M write-down, Q2 cost of sales was 8.1% of sales (H1: 8.4%; our calculation). The 10-Q names higher Roche royalties as the main driver. Management says cost of sales will keep rising as pre-approval inventory runs out. Our view: some margin investors see today will not last.
  2. Receivables and inventory vs revenue (10-K and 10-Qs; days are our calculation). Trade receivables rose 43% in six months ($134M → $192M) while quarterly sales rose 13%. Days outstanding went from about 39 to 48. About 91% of the six-month receivables increase came in Q1 (receivables $187M at the end of March; ~54 days on Q1 sales of $311M, when sales dipped). In Q2, receivables rose only 3% while sales rose 17%, and days fell back to ~48. Inventory rose 33%. The fifth customer’s rise to ~13% may explain part of it. At the end of Q3, receivables were $227M on sales of $431M, again about 48 days (our calculation).
  3. Stock pay vs free cash flow. Stock pay of about $98M a year (10-K; about 10% of sales) is excluded from the “one-time” framing management uses. Unrecognised stock pay is $358M (10-Q). The 3-year burn rate is 2.7% of shares a year (proxy). Equity overhang after the 2026 plan is 11.3% (proxy).
  4. “Adjusted” framing (earnings releases). Madrigal reports GAAP only. But every quarter it calls licensing upfronts “one-time” ($54.3M in Q1 2026, of which $49.3M was the expensed part of the $60M Ribocure upfront; $25.0M in Q2; CSPC $120M and Pfizer $50M in 2025) and quantifies their per-share impact within GAAP losses. Our view: licensing is the strategy, so treat about $100–200M a year as recurring.
  5. Estimate catch-ups (10-Q reserve note). Reserves of $176M (from $99M) carry the rebate estimate. Prior-year reserve adjustments were small and favourable (−$5.5M in H1 2026, which raises revenue). Rising rebate accruals ($152M vs $91M) were a source of operating cash in H1 2026.
  6. Capitalised costs and goodwill (10-Q). There are none of note: intangibles are $7M, R&D is expensed, and $10.7M of the Ribocure upfront is capitalised as prepaid R&D.
  7. Material weaknesses (10-K). None. Controls were judged effective at end-2025.
  8. Accounting-policy changes and revisions (Q1 2026 10-Q). In Q1 2026 the company revised loss per share for all prior periods. It had wrongly left the pre-funded warrants and convertible preferred out of the share count, for example FY2025 −$12.85 → −$10.15. It called this immaterial. Expense disclosure was expanded in Q1 2026.
  9. Receivable sales or factoring. None disclosed (10-K, 10-Q).
The share-count bridge: 29.36M economic shares, 31.03M fully diluted

Share-count bridge (Fact, 10-Q Q3 2026; option and RSU counts as at the end of June; Our calc. at $396.32):

Shares (M) Value ($B)
Common stock outstanding (Q3 10-Q cover) 23.23 9.21
+ Series A/B convertible preferred (1:1; Baker Bros) 2.37
+ Pre-funded warrants ($0.0001 exercise; mostly Baker Bros) 3.61
+ Earned PSUs awaiting settlement (end of September) 0.15
= Economic basic shares (the company’s Q3 weighted-average EPS denominator was 29.25M) 29.36 11.63
+ Options, RSUs and unearned PSUs (treasury method) 1.67
= Fully diluted 31.03 12.30

Market value on common shares is $9.2B; including the convertible preferred and pre-funded warrants, which convert one-for-one, it is $11.6B, about 26% more.

Confidence: high on the facts, medium on interpretation.

6. Valuation today

At about 6.9× this year’s expected sales, the market is not paying for a full F4c success, and today’s price sits low in our range of outcomes, roughly where early generics and a weak exit multiple would leave it. The gap to our median depends on the market still paying a growth-biotech multiple in 2030.

The facts behind this

On all economic shares, Madrigal is valued at about $11.0B EV, or 6.9× this year’s expected sales (nine-month actual plus our median Q4) and about 3.9× 2028 consensus sales. That is in line with high-growth commercial biotechs. The market is not paying for a full F4c success.

EV = $11.63B economic equity − $0.96B cash + $0.35B debt = $11.02B (fully diluted: $11.68B; Nov 3 close).

Company (late October) EV ($B) EV/sales TTM Fwd P/S 3-yr rev. growth (cons.)
Madrigal 12.2 9.5× 8.3× (2026E) ~44% (2025–28)
Alnylam (editors hold) 29.7 6.2× 4.7× ~31%
Insmed 20.0 17.6× 8.4× ~84%
Axsome 7.5 9.7× 6.4× ~49%
Krystal Biotech 8.1 18.5× 16.8× ~31%

Peer data: StockAnalysis, late October 2026 (medium confidence; peers’ forward multiples are price/sales). Madrigal’s figures are ours, computed on 29.17M economic shares. On consensus: 18× 2028 EV/EBIT and 21× 2028 EPS, with little tax payable at first: the 10-K shows $1.18B of federal NOLs (plus $0.98B state, $0.13B foreign and $82M of R&D credits). At 2028 consensus EBIT of $663M, the federal NOLs shelter only about two years of profit.

Against its own history (Fact, closing prices): the 52-week closing high was $602.83, in December 2025. At the Nov 3 close the stock is −32% year to date (the XBI biotech index was +23% to late October). It fell 16% from late September to late October with no company-specific news we could find. Possible reasons are positioning ahead of the lanifibranor data and Q3 (Our view, low confidence). Moves on results days: −11% after the Q4 2025 results (gross-to-net), +7% after Q1, −10% after Q2 (worry that growth is shifting to a slower pace) and −8% after Q3 (the first quarterly profit; the stock was up as much as 12% during the day before it reversed).

What the price implies (Our view, from our simulation):

  • The median path has 2030 sales of ~$4.1B and a net margin of ~26%. At the median exit multiple of 5.1× next year’s sales, that is worth ~$860 a share, about 118% above today’s price and about 52% above the $567 hurdle.
  • Clearing the hurdle needs an exit multiple of roughly 3.3× or more, below the median, with generic entry around the median 2034.
  • Today’s price sits near the 7th percentile of outcomes, roughly what an early generic entry (~2032) combined with a weak exit multiple would give.
  • At the median generic-entry date only ~3 years of protection remain in 2030. The patent discount takes the exit from ~7.0× to ~5.1× forward sales. That is still above companies that close to patent expiry (~2–2.7×: BMRN, UTHR, JAZZ, BIIB, INCY), because our model keeps at least half of Madrigal’s own multiple as the floor.
  • A cash-flow cross-check is much lower: valuing only the cash Rezdiffra earns until generics arrive, discounted at 9%, gives a median of ~$340 (only 26% beat the hurdle). So the result relies on the market still paying a growth-biotech multiple in 2030.
Named analysts: 19 analysts, average 12-month target $685

Analyst views (Fact/Analyst): 19 analysts. The mix is 15 Strong Buy, 3 Buy, 1 Hold. The average 12-month target is $685 (range $533–$962).

  • Bull: Barclays analyst Eliana Merle ($962 target, in September).
  • Contrarians: BofA’s Jason Zemansky (Neutral, cut to $533 in October; a pre-Q3 estimate update across BofA’s coverage; earlier 2026 cuts cited competition). Wolfe Research’s Andy Chen downgraded to Peer Perform in January 2026 ($572 target) on valuation and competition, doubting a $6B peak (Wolfe is not reflected in the S&P count; its January view may be stale).
  • Note the gap: the consensus 12-month target is 58% above the price. Either the sell side is slow, or the market is discounting F4c and competition more heavily.

Confidence: medium.

7. Value at end-2030: the simulation

Our simulation puts the middle outcome at about $860 a share at end-2030, well above the $567 hurdle. There is an 84% chance of beating a 9% yearly return and a 7% chance of a loss. The result rests mainly on the generic-entry year, the 2028 confirmatory trial and the market’s valuation level in 2030. The full result table is in the Our view box at the top.

Method: Valued directly at end-2030.

Implied end-2030 multiple: our end-2030 value implies 5.4× (P25–P75 4.1–7.3×) 2031 sales; today: 5.3×. On 2031 earnings: 26.5× (P25–P75 20.9–35.2×); today: 29.4×.

Top 5 assumptions. Our model uses many more inputs; the main ones are shown here.

  1. Patients: F2–F3 net adds start at today’s ~6,500 a quarter and bend down as the diagnosed pool fills and rivals launch; the share of diagnosed patients on therapy at once is capped at a central 25% (range 15–35%). The pool starts at about 545,000, the company’s own estimate rolled forward to the end of September.
  2. Generic entry: central 2034, range ~2032–2038, after patent litigation that can start in 2028.
  3. The 2028 confirmatory MAESTRO-NASH trial succeeds about 93% of the time; the F4c cirrhosis label is roughly a coin flip and adds little revenue before 2030.
  4. Exit multiple: Madrigal’s own forward-sales multiple, adjusted for growth, with the premium over peers that protection does not explain faded, and one cut for the patent life left (protection counted once), keeping at least half of its own multiple as the floor.
  5. Takeovers are included at historical base rates.

The most influential events.

  • The 2028 confirmatory trial failing: rare, but the largest single downside (see “What would move the result”).
  • The F4c cirrhosis label succeeding or failing in 2027–28.
  • A takeover: it happens in about a quarter of runs and supplies about a tenth of the median.
  • Rival launches from 2028 (lanifibranor, FGF21 injections, incretins), which take a share of new starts and add payer pressure.

Sensitivities on the same model and inputs:

End-2030 value per share (undiscounted) P10 P25 P50 P75 P90 Mean P(beat 9%/yr) P(loss)
Analysts’ “adds halve” setting $345 $471 $625 $840 $1,121 $685 59% 15%
Neutral market mood at the exit $530 $700 $890 $1,170 $1,550 $965 88% 7%
Cross-check: cash flow to patent expiry, 9% $194 $255 $340 $585 $1,223 $535 26% 61%
The facts behind this

How it works: the simulation runs Madrigal’s business 50,000 times, quarter by quarter to Dec 31, 2030. Each run draws patient adds, the size of the diagnosed patient pool, net price, rival launches, trial outcomes, costs, the generic-entry year and the exit multiple from sourced ranges, and records the value per share.

The exit multiple in our model:

  • starts from Madrigal’s own forward-sales multiple since it reached its current size (measured against the S&P 500’s valuation). This own-history anchor is 7.9×, measured on all economic shares including the latest year;

  • is adjusted for growth versus what the market expects, has the part of its premium over peers that protection does not explain faded toward the peer level (half-life 2.7 years), and is then cut once for the shorter patent life, at about 6.6% of the multiple per year of protection, as US biotech multiples show;

  • lands at a median of 5.1× next year’s sales (P25–P75 3.9–6.6×).

  • Returns: the median is about 21% a year (P25 +13%, P75 +29%). The hurdle is $567: 9% a year over the 4.2 years to Dec 31, 2030.

  • Patients and sales: today’s ~6,500 net adds a quarter bend to a median ~4,200 by 2030 as the diagnosed pool fills and rivals launch. That gives ~142,000 F2–F3 patients and ~$4.1B of sales in 2030.

  • F4c adds little by 2030 (median ~$0.1B of sales; ~$0.4B at P75) because the label would arrive in 2028–29.

  • Against the consensus from before the Q3 results, our revenue is about 4% above for FY2026 and 4% above for FY2028. FY2027 is about 11% above, because our model starts from the stronger Q3 and keeps adds at today’s pace in the near term.

  • The biggest swings are the generic-entry year and the 2028 confirmatory trial (see “What would move the result”).

Confidence: the simulation shows the spread its inputs imply, not a forecast. Confidence applies to the inputs: medium for sales and margin, low for the multiple and the trial probabilities.

8. Management and governance

Management has executed the launch well. Pay rewards sales and dealmaking rather than profit or returns on licensing, which is one reason our model treats licensing spend as recurring. A specialist-fund register around Baker Bros makes a sale of the company realistic, which is why takeovers sit in the simulation.

The facts behind this

Management has executed the launch well. The board is strongly influenced by Baker Bros, the chairman’s firm: it holds two of nine seats and about a quarter of the economic interest, but under 10% of the votes. Other specialist funds are large holders without board seats. The annual bonus rewards sales and dealmaking rather than profit. Long-term pay is tied to the share price (options, relative-TSR PSUs, CEO price-hurdle PSUs), but nothing rewards operating profit, cash flow or returns on licensing spend.

Track record (Fact). CEO Bill Sibold (ex-head of Sanofi Genzyme) joined in September 2023. He has delivered approval, the launch, the EU approval and beats against consensus. CFO Mardi Dier has been in place throughout.

Credibility events (Our view). There are no restatements or missed guidance. The minor items are the share-count revision of past EPS, the “one-time” framing of recurring licensing charges, and the “protection into 2045” claim, which overstates how durable method-of-use patents are.

What pay rewards (Fact, proxy). CEO pay was $19.2M in 2025, and the 2025 bonus paid 194.7% of target, with sales objectives the largest contributor. Our view: long-term pay is share-price-linked, but nothing rewards operating profit, cash flow or returns on licensing spend. The pipeline goal pays for signing deals, not for what they are worth.

Voting and economic control (Fact). Baker Bros (chairman Julian Baker and director Raymond Cheong) holds about 25% of the economic shares but about 9.2% of votes, and two of nine board seats; six of nine directors are independent. The board is staggered (three classes). Our view: a specialist-fund register makes a sale of the company a realistic option. It also means a large overhang if those funds exit.

Other management changes: a new chief accounting officer (Jan 2026); the founder moved from R&D to a consulting role but stays on the board
  • A new chief accounting officer, Rita Thakkar (BMS chief audit officer 2019–24, most recently SVP Global Business Operations), joined in January 2026.
  • The founder and former head of R&D, Rebecca Taub, handed over R&D in April 2025 (to CMO David Soergel). She was an employed adviser until June 2026 and has been a consultant since July 2026 (one-year term; fee not disclosed in the filed agreement). She remains on the board.
Bonus weights, long-term pay mix and the CEO's hiring PSUs (proxy)
  • Bonus weights: sales objectives 50% (paid 114 points, 228% of target, the largest contributor); pipeline expansion (deals signed) 15%, paid at 150%; intellectual property (a patent issued) 15%, paid at 200%; EU approval 7.5%; US market access (“favorable gross to net”) 5%; publications 3.5% and German launch 4% complete the weights.
  • Long-term pay is one-third relative-TSR PSUs (vs the Nasdaq Biotech Index), one-third RSUs and one-third options.
  • The CEO’s hiring PSUs paid out on absolute share-price hurdles. All three have now been hit (February 2025, December 2025 and July 2026), each worth 50,000 shares: 150,000 shares, about $59M at today’s price, with settlement deferred to 2027–29.

Insider sales and plan timing (Fact, Forms 4). There were no open-market purchases. Insiders sold about $40M in 2026 through mid-September, plus about $41M in Q4 2025. Most of it was founders exercising expiring options; the CEO’s discretionary sales were small.

Who sold, under which plans, and when (Forms 4)
  • Founders Taub and Friedman (husband and wife, about 7.6% together) were the largest sellers: $24M in 2026, under plans adopted in September 2025, selling near the December–January high ($512–$555). These were exercise-and-sell of $15.80 options expiring in March 2027 (the grant is now fully exercised). Friedman, the former CEO, left the board in June 2026. In September he filed notice to sell 50,000 more shares, about $25.8M, from exercising other options, under a trading plan adopted in August (Form 144).
  • The CEO sold $9.1M in 2026. About $6.3M were automatic tax-withholding sales (January, March, July on the third PSU tranche, and September on RSU vesting); only ~$2.8M was discretionary.
  • The discretionary sales came under a plan adopted in June 2026, in the open window after Q1 and about two months before the Q2 report (−10%). Its first and only sales so far came in September at $533–$546 (5,221 shares, $2.8M; plan maximum 6,706 shares). Our view: the timing is within the rules, and the size is small against holdings of about 198,000 shares.
  • Director Kenneth Bate sold $8M in November 2025 with no plan box ticked. He was still a director, sold the day after Q3 results (open window), and the sales were exercise-and-sell of all his remaining options, including one expiring Jul 2026; he later left the board (proxy).
Baker Bros' holdings, board changes and other large holders (proxy, filings)
  • Baker Bros holds 2.14M common shares, 2.37M non-voting preferred and 2.71M pre-funded warrants: about 7.2M of 29.2M economic shares. The preferred is non-voting and blocked at 4.99%, and the pre-funded warrants are blocked at 9.99%, so Baker’s ~2.14M common shares carry about 9.2% of votes.
  • Board: Independent Chairman Julian Baker; Raymond Cheong sits on the compensation committee and chairs the science committee. Since the proxy, Friedman left the board in June 2026 and John Reed of J&J joined in August.
  • Other holders (percentages from the proxy table): Avoro 9.9%, RTW 8.7%, Paulson 7.4%, Janus 6.9%, Vanguard 6.8%, BlackRock 5.2%. Several are based on stale 13G filings (Avoro Feb 2024, RTW Nov 2024, Vanguard Feb 2024, BlackRock Jan 2024); Vanguard’s Mar 2026 13G/A reports 0.0% after it split its reporting, so its holding is now reported by separate entities.

Confidence: high.

9. Signposts

Q3 passed the first test on the business: sales of $431.3M against about $404M expected and about 6,850 net new patients, even though the stock fell that day. Next come lanifibranor’s Phase 3 data in Q4 2026 and the 2027 rebate level. The decisive ones are the patent-extension decision and the 2027–28 outcomes readouts, because generic timing and the confirmatory trial move the result most.

The signposts: what counts as on track or broken
# Signpost On track Broken When
1 Q3 2026 results (passed) Sales $431.3M vs ~$404M consensus; net adds ~6,850 (49,000 → 55,850); gross-to-net ~32.5%; first operating profit — Reported
2 Lanifibranor NATiV3 topline (Inventiva) Modest efficacy, weight-gain/edema problems; also watch an unassessed SUSAR (suspected unexpected serious adverse reaction) Inventiva disclosed Clean, strong data on both endpoints Q4 2026
3 Q4 2026 and the 10-K notes Receivables days keep falling; the fast-growing customer explained; rebates at the low end of the range for 2026 Receivables keep outrunning sales; rebates above the range Feb 2027
4 FY2026 results and 2027 payer contracts Gross-to-net stable into 2027; first operating profit in sight Another step-up in rebates; no profit timeline Feb 2027
5 Patent term extension decision Long extension (ideally the ’861 patent toward 2038; generic timing is the simulation’s largest driver) Short or denied Unknown, 2026–27
6 MAESTRO-NASH OUTCOMES (F4c) topline Clear benefit on liver outcomes (simulation median ~$955 with success) Miss or marginal result (~$782 without) Late 2027 (company)
7 Paragraph IV notices Few filers; strong patent posture Several filers attacking the 2033 patents From Mar 14, 2028
8 MAESTRO-NASH 54-month confirmatory Positive; full approval Negative; label at risk (the simulation’s largest single event: median value ~$135 a share if it fails) 2028

10. Open questions

The answers that would most change our inputs are the real start and stop rates of patients, how the Medicare and Medicaid share of revenue is changing and the patent extension chosen.

The full list of open questions
  • How many new patients start and stop each quarter, and how long they stay on therapy in practice, not just the 60–70% one-year figure.
  • How the Medicare and Medicaid share of revenue is changing (the CEO’s range, for volume, is a year old), which drives exposure to the IRA and to most-favoured-nation pricing.
  • Which patent Madrigal chose for the term extension, and the resulting date (the applicant seeks “1,594 days or 5 years”).
  • Who the fast-growing fifth customer is (its letter changes between filings), and why receivables rose so sharply in Q1.
  • The F4c event target and the statistical plan; what result counts as a commercially useful win.
  • The 2027 gross-to-net trajectory once the 2026 contracts roll over.
  • The annual budget and hurdle for licensing deals; what “preparing for profitability” means in numbers.
  • Whether Baker Bros or the other specialist funds have signalled exit or sale preferences, and current holdings for funds whose 13Gs are stale.
  • How net adds behave as Wegovy use grows and rivals approach: the simulation’s slowdown (to ~3,900 a quarter by 2030) is a modelled assumption, not yet a trend in the data.
  • Why the stock fell 16% in October with no news.

Sources

Sources (accessed Oct 25, Nov 3 and Nov 4, 2026): 25 filings, releases and data sources
  • Madrigal 10-K FY2025 (Feb 19, 2026)
  • 10-Qs Q1, Q2 and Q3 2026 (May 6, Jul 30, Nov 3, 2026)
  • 8-K earnings releases Q4 2025–Q3 2026
  • 8-Ks Jul 22, 2025 (Blue Owl loan), Jan 30, 2026 (Roche amendment), Dec 11, 2025, Apr 28, Jun 17, Aug 12, 2026
  • DEF 14A (Apr 28, 2026)
  • Forms 4 Nov 2025–Sep 2026 and Form 144, Sep 28, 2026 (SEC EDGAR)
  • Q3 2025 earnings call transcript (Stock Analysis)
  • Madrigal’s Connecticut price notice (Apr 2026)
  • Federal Register, Rezdiffra regulatory review period (Jan 27, 2026)
  • Q2 2026 earnings call transcript (Investing.com) and MarketBeat call summary
  • Q3 2026 earnings call transcript (MarketBeat, Nov 3, 2026)
  • Nasdaq price history (MDGL closes to Nov 3, 2026)
  • MarketScreener and StockAnalysis (consensus, targets, peer statistics, Oct 23 close)
  • Yahoo Finance price history (MDGL, XBI)
  • ad-hoc-news (UBS, Oct 14, 2026)
  • Investing.com (Q4 2025 reaction, gross-to-net)
  • Simply Wall St (Wolfe downgrade)
  • BioSpace/Fierce/BioPharma Dive (Wegovy, Leerink)
  • Inventiva releases (NATiV3 timing)
  • Boehringer/Zealand releases (survodutide)
  • Novo Nordisk Q2 2026 presentation and MedCity News (Akero)
  • Madrigal IR (Oct 6 and Oct 20, 2026 releases)
  • BIO/Informa/QLS Clinical Development Success Rates 2011–2020
  • Estes et al., Hepatology 2018

Updates

  • : Corrected Nov 4, 2026: the legal table said Madrigal was not a party to any material legal proceedings. The Q3 10-Q, filed the day we published, discloses a former employee's whistleblower-retaliation complaint, filed in October, which Madrigal disputes. We also made some updates: added the CEO's range for Rezdiffra's payer mix by volume from the Q3 2025 call, dated our 'clean accounts' wording to the end-2025 audit, updated the list price, the net price per patient and the cirrhosis trial date in the pipeline table, and added a founder's share-sale notice. No model results changed.

About Madrigal Pharmaceuticals: Website (external site)Investor relations (external site)SEC filings (external site)

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

Disclosure: one or more of our editors own shares of companies named in this article (MDGL, ARWR, VKTX, ALNY) as a long-term investment. For education only, not investment advice. Full disclaimer.

Spot an error or have a question? · Corrections policy